Literature DB >> 15693851

Distinct expression patterns of claudin-1 and claudin-4 in intraductal papillary-mucinous tumors of the pancreas.

Munetoshi Tsukahara1, Hideo Nagai, Tomoko Kamiakito, Hirotoshi Kawata, Norio Takayashiki, Ken Saito, Akira Tanaka.   

Abstract

The expression of claudin-4 was investigated in human pancreas, pancreatic ductal adenocarcinomas, and intraductal papillary-mucinous tumors of the pancreas (IPMT), and compared with that of claudin-1. In human adult pancreatic specimens, both claudin-1 and claudin-4 were immunohistochemically found in main and branching pancreatic ducts, terminal ductules and acinic cells, with the exception of endocrine cells. Of 12 cases of pancreatic ductal adenocarcinoma, 11 (92%) had positive immunostaining for claudin-4, and seven (58%) for claudin-1. In 44 lesions of 22 cases of IPMT, including six hyperplastic foci distant from the main lesions, clauidin-1 was positive in three out of six (50%) hyperplastic foci, 14 out of 17 (82%) adenomas, three out of 10 (30%) borderline tumors, two out of six (33%) non-invasive carcinomas, and one out of five (20%) invasive carcinomas, producing a statistically negative correlation with histological tumor grades. In contrast, claudin-4 was negative in the six hyperplastic foci, and positive in four out of the 17 (24%) adenomas, five out of the 10 (50%) borderline tumors, five out of the six (83%) non-invasive carcinomas, and four out of the five (80%) invasive carcinomas, producing a statistically positive correlation with histological tumor grades. On study of IPMT subtypes, claudin-1 was positive in nine out of 10 (90%) clear-cell types, seven out of 20 (35%) dark-cell types, and four out of eight (50%) compact-cell types. In contrast, claudin-4 was positive in two out of the 10 (20%) clear-cell types, 13 out of the 20 (65%) dark-cell types, and three out of the eight (38%) compact-cell types. These distinct expression patterns of claudin-1 and claudin-4 suggest that both claudins serve as useful molecular markers for the tumor classification of IPMT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15693851     DOI: 10.1111/j.1440-1827.2005.01793.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Dynamic distribution of claudin proteins in pancreatic epithelia undergoing morphogenesis or neoplastic transformation.

Authors:  Joby J Westmoreland; Yiannis Drosos; Jacqueline Kelly; Jianming Ye; Anna L Means; M Kay Washington; Beatriz Sosa-Pineda
Journal:  Dev Dyn       Date:  2012-01-31       Impact factor: 3.780

2.  Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  J Hepatol       Date:  2008-05-22       Impact factor: 25.083

3.  Correlation between Claudins Expression and Prognostic Factors in Prostate Cancer.

Authors:  Kyung Won Seo; Young Kee Kwon; Byung Hoon Kim; Chun Il Kim; Hyuk Soo Chang; Mi Sun Choe; Choal Hee Park
Journal:  Korean J Urol       Date:  2010-04-20

4.  Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma.

Authors:  Ylermi Soini; M Eskelinen; P Juvonen; V Kärjä; K M Haapasaari; A Saarela; P Karihtala
Journal:  Tumour Biol       Date:  2014-02-12

5.  Claudin expression in pancreatic endocrine tumors as compared with ductal adenocarcinomas.

Authors:  Katalin Borka; Péter Kaliszky; Erzsébet Szabó; Gábor Lotz; Péter Kupcsulik; Zsuzsa Schaff; András Kiss
Journal:  Virchows Arch       Date:  2007-04-12       Impact factor: 4.064

Review 6.  Intraductal papillary mucinous neoplasm of the pancreas: an update.

Authors:  Shu-Yuan Xiao
Journal:  Scientifica (Cairo)       Date:  2012-11-28

Review 7.  Claudin-1, A Double-Edged Sword in Cancer.

Authors:  Ajaz A Bhat; Najeeb Syed; Lubna Therachiyil; Sabah Nisar; Sheema Hashem; Muzafar A Macha; Santosh K Yadav; Roopesh Krishnankutty; Shanmugakonar Muralitharan; Hamda Al-Naemi; Puneet Bagga; Ravinder Reddy; Punita Dhawan; Anthony Akobeng; Shahab Uddin; Michael P Frenneaux; Wael El-Rifai; Mohammad Haris
Journal:  Int J Mol Sci       Date:  2020-01-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.